Bayer AG (OTCMKTS:BAYRY) – Investment analysts at Jefferies Group reduced their FY2017 earnings estimates for shares of Bayer in a research report issued to clients and investors on Tuesday. Jefferies Group analyst J. Holford now forecasts that the company will post earnings of $1.97 per share for the year, down from their previous forecast of $2.21. Jefferies Group also issued estimates for Bayer’s FY2018 earnings at $2.19 EPS, FY2019 earnings at $2.39 EPS, FY2020 earnings at $2.57 EPS and FY2021 earnings at $2.76 EPS.
A number of other equities analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Bayer from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 31st. BNP Paribas raised shares of Bayer from a “neutral” rating to an “outperform” rating in a research report on Monday, September 25th. Finally, ValuEngine lowered shares of Bayer from a “buy” rating to a “hold” rating in a research report on Friday, September 22nd. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $36.00.
Bayer (OTCMKTS:BAYRY) last issued its quarterly earnings data on Thursday, October 26th. The company reported $0.43 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.29 by $0.14. Bayer had a net margin of 10.88% and a return on equity of 18.53%. COPYRIGHT VIOLATION WARNING: “Bayer AG Expected to Post FY2017 Earnings of $1.97 Per Share (BAYRY)” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3143813/bayer-ag-expected-to-post-fy2017-earnings-of-1-97-per-share-bayry.html.
Bayer Company Profile
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.